A phase 1/2 open-label, single ascending dose trial of a self-complementing optimized adeno-associated virus serotype 8 Factor IX gene therapy (AskBio009) in adults with haemophilia B
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs AskBio 009 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Asklepios BioPharmaceutical; Baxalta; Baxter Healthcare Corporation; Shire
- 06 Nov 2017 Planned End Date changed from 1 Nov 2030 to 28 Oct 2030.
- 06 Nov 2017 Planned primary completion date changed from 1 Nov 2030 to 28 Oct 2030.
- 07 Sep 2016 Planned End Date changed from 1 Nov 2029 to 1 Nov 2030.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History